張健
系統(tǒng)生物信息學(xué),、藥物化學(xué)及化學(xué)生物學(xué)組
電話(huà)：021-63846590-776922
郵箱：[email protected]
張健，上海交通大學(xué)特聘教授,，藥物化學(xué)與生物信息學(xué)中心主任,，國(guó)務(wù)院學(xué)位委員會(huì)學(xué)科評(píng)議組成員,，國(guó)家杰出青年基金獲得者。2002年畢業(yè)于北京大學(xué)藥學(xué)院,，獲藥學(xué)學(xué)士學(xué)位,，北京大學(xué)優(yōu)秀畢業(yè)生，免推至中國(guó)科學(xué)院上海藥物研究所,， 2007年獲藥學(xué)博士學(xué)位,，全國(guó)優(yōu)秀博士論文。2009年回國(guó)受聘于上海交通大學(xué)醫(yī)學(xué)院至今,。張健教授主要從事藥物設(shè)計(jì),、藥物化學(xué)和化學(xué)生物學(xué)研究，特別是精準(zhǔn)靶標(biāo)識(shí)別和First-in-class原創(chuàng)藥物先導(dǎo)發(fā)現(xiàn)等方向做出了一系列突破性成果,。以通訊作者在包括Nat Chem Biol, Sci Adv, Am J Hum Genet, Nucleic Acids Res, J Med Chem等國(guó)際學(xué)術(shù)雜志上發(fā)表SCI論文90余篇,。近年來(lái)代表性工作包括：(1)發(fā)展臨床樣本靶標(biāo)識(shí)別方法識(shí)別抗腫瘤新靶標(biāo),；(2)發(fā)展變構(gòu)藥物設(shè)計(jì)方法發(fā)現(xiàn)多種全新變構(gòu)活性分子,；(3)研發(fā)抗腫瘤新靶標(biāo)首個(gè)First-in-class藥物先導(dǎo),，如SIRT6激動(dòng)劑MDL-800、APC/Asef互作首個(gè)抑制劑MAIT-203等,。他引超過(guò)5000次,，H因子為43，獲國(guó)內(nèi)外專(zhuān)利9項(xiàng)(第一發(fā)明人5項(xiàng)),。受邀以通訊作者在國(guó)際頂尖綜述雜志Chem Rev,、Chem Soc Rev撰寫(xiě)變構(gòu)藥物機(jī)制綜述，均作為封面文章重點(diǎn)推薦,；受美國(guó)化學(xué)會(huì)旗艦期刊Acc Chem Res特邀回顧10年來(lái)引領(lǐng)變構(gòu)藥物設(shè)計(jì)領(lǐng)域發(fā)展的貢獻(xiàn),；受Springer-Nature出版社邀請(qǐng)作為主編撰寫(xiě)國(guó)際首本變構(gòu)藥物發(fā)現(xiàn)類(lèi)書(shū)Protein Allostery in Drug Discovery；常年擔(dān)任Science,、Nat Chem等70余種SCI期刊審稿人,，澳大利亞Austrian Science Fund (FWF)等基金和西班牙University of Barcelona等學(xué)校Tenure考核的國(guó)際評(píng)審人。由于在“精準(zhǔn)靶標(biāo)識(shí)別和First-in-class藥物先導(dǎo)發(fā)現(xiàn)”方面的貢獻(xiàn),，獲美國(guó)化學(xué)會(huì)Excellent Research Advisor,、中國(guó)藥學(xué)會(huì)生物醫(yī)藥創(chuàng)新獎(jiǎng)、2017年中國(guó)十大科技新銳人物,、Roche Creative Chemistry Award和藥明康德生命化學(xué)研究獎(jiǎng)等榮譽(yù),。先后主持國(guó)家自然科學(xué)基金委重大項(xiàng)目、國(guó)家重大新藥創(chuàng)制等項(xiàng)目,。
近5年代表性文章 (*為通訊作者)
1.
Lu S, Shen Q, Zhang J*. Allosteric methods and their applications: facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms. Acc Chem Res. 2019, 52(2): 492-500.
2.
Huang Z, Zhao J, Deng W, Chen Y, Shang J, Song K, Zhang L, Wang C, Lu S, Yang X, He B, Min J, Hu H, Tan M, Xu J, Zhang Q, Zhong J, Sun X, Mao Z, Lin H, Xiao M, Chin YE, Jiang H, Xu Y*, Chen G*, Zhang J*. Identification of a cellular active SIRT6 allosteric activator. Nat Chem Biol. 2018, 14(12): 1118-1126.
3.
Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, Song K, Liu X, Zhang Q, Chen Y, Chinn YE, Wu G, Li J, Chen G, Yu J*, Zhang J*. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol. 2017, 13(9):994-1001.
4.
Huang M, Song K, Liu X, Lu S, Shen Q, Wang R, Gao J, Hong Y, Li Q, Ni D, Xu J, Chen G, Zhang J*. AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Res. 2018, 46: 451-458.
5.
Shen Q, Cheng F, Song H, Lu W, Zhao J, An X, Liu M, Chen G, Zhao Z*, Zhang J*. Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7,000 cancer genomes. Am J Hum Genet. 2017, 100(1): 5-20.
6.
Lu S*, Ni D, Wang C, He X, Lin H, Wang Z*, Zhang J*. Deactivation pathway of Ras GTPase underlies conformational substates as targets for drug design. ACS Catalysis. 2019, 9(8): 7188-7196.
7.
Liu X, Lu S, Song K, Shen Q, Ni D, Li Q, He X, Zhang H, Wang Q, Chen Y, Li X, Wu J, Sheng C, Chen G, Lu X*, Zhang J*. Unraveling allosteric landscapes of allosterome with ASD. Nucleic Acids Res. 2020, 48: 394-D401.
8.
Song K, Li Q, Gao W, Lu S, Shen Q, Liu X, Wu Y, Wang B, Lin H, Chen G, Zhang J*. AlloDriver: a method for the identification and analysis of cancer driver targets. Nucleic Acids Res. 2019, 47: 315-321.
9.
Yang X, Zhong J, Zhang Q, Qian J, Song K, Ruan C, Xu J, Ding K, Zhang J*. Rational Design and Structure Validation of a Novel peptide Inhibitor of the Adenomatous Polyposis Coli (APC)-Rho Guanine Nucleotide Exchange Factor 4 (Asef) Interaction. J Med Chem. 2018, 61(17): 8017-8028.
10.
Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R*, Zhang J*. Ras conformational ensembles, allostery and signaling. Chem Rev. 2016, 116(11): 6607-6665.
